Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

•Final PFS data and second pre-planned interim analysis of OS and safety from J-ALEX.•Sustained improvement in IRF-assessed PFS demonstrated with alectinib.•Superiority of alectinib to crizotinib not concluded at second interim OS analysis.•Fewer alectinib-treated patients experienced grade ≥3 adver...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2020-01, Vol.139, p.195-199
Hauptverfasser:	Nakagawa, Kazuhiko, Hida, Toyoaki, Nokihara, Hiroshi, Morise, Masahiro, Azuma, Koichi, Kim, Young Hak, Seto, Takashi, Takiguchi, Yuichi, Nishio, Makoto, Yoshioka, Hiroshige, Kumagai, Toru, Hotta, Katsuyuki, Watanabe, Satoshi, Goto, Koichi, Satouchi, Miyako, Kozuki, Toshiyuki, Koyama, Ryo, Mitsudomi, Tetsuya, Yamamoto, Nobuyuki, Asakawa, Takashi, Hayashi, Morihiko, Hasegawa, Wakako, Tamura, Tomohide
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Alectinib ALK-positive Anaplastic Lymphoma Kinase - metabolism Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - metabolism Carbazoles - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Cohort Studies Crizotinib Crizotinib - administration & dosage Disease Progression Female Follow-Up Studies Humans J-ALEX Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged NSCLC PFS Piperidines - administration & dosage Prognosis Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!